The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance. (January 2023)

• Record Type: Journal Article
• Authors: Canar, Jorge; Darling, Kennedy; Dadey, Ryan; Gamero, Ana M.
• Is Part Of: Cytokine. Volume 161(2023)
• Publication Date: 2023-01
• Subjects: Interferons -- STAT2 -- Tumor -- Microenvironment -- Chemoresistance; type I interferons IFN-I -- STAT Signal Transducer and Activator of Transcription; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2022.156081
• Languages: English
• ISSNs: 1043-4666

Abstract

Abstract: The tumor microenvironment consists of tumor cells, extracellular matrix, blood vessels, and non-tumor cells such as fibroblasts and immune cells. Crosstalk among components of this cellular ecosystem can transform non-malignant cells and promote tumor invasion and metastasis. Evidence is accumulating that the transcription factor STAT2, a downstream effector of type I interferon (IFN-I) signaling, can either inhibit or promote tumorigenesis depending on the unique environment presented by each type of cancer. STAT2 has long been associated with the canonical JAK/STAT pathway involved in various biological processes including reshaping of the tumor microenvironment and in antitumor immunity. This dichotomous tendency of STAT2 to both inhibit and worsen tumor formation makes the protein a curious, and yet relatively ill-defined player in many cancer pathways involving IFN-I. In this review, we discuss the role of STAT2 in contributing to either a tumorigenic or anti-tumorigenic microenvironment as well as chemoresistance.